Company Encyclopedia
View More
name
Jade Biosciences
JBIO.US
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage.
1.897 T
JBIO.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Jade Biosciences Advances Autoimmune Therapies

    Jade Biosciences, Inc. reported a Q3 net loss of $25.2 million, attributed to increased R&D expenses. The company bolstered its financial position with a $135 million private placement, resulting in a cash position of $325.6 million. Significant progress was made in its clinical pipeline, with promising data for JADE101 and the introduction of JADE201. JADE101 is in Phase 1 trials, and JADE201 will begin trials in 2026. The company is optimistic about future growth in the autoimmune disease treatment market.

    Tip Ranks·
    US
    JBIO
    -1.50%
    Tip Ranks·
    US
    JBIO
    -1.50%

    Jade Biosciences Files For Offering Of Up To 16.1 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing

    Nov 14 (Reuters) - Jade Biosciences Inc:* JADE BIOSCIENCES INC FILES FOR OFFERING OF UP TO 16.1 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: Further company coverage:

    Reuters·
    US
    JBIO
    -1.50%
    Reuters·
    US
    JBIO
    -1.50%

    Jade Biosciences Reports Q3 2025 Financial Results

    Jade Biosciences reported a Q3 2025 net loss of $25.2 million due to increased R&D and G&A expenses. The company completed a merger and reverse stock split, presented promising preclinical data, and initiated a Phase 1 study. They raised $135 million to extend their cash runway into 2028. Analysts rate JBIO stock as a Buy with a $28 target, but Spark's AI Analyst views it as Underperform due to financial challenges. Jade Biosciences focuses on therapies for autoimmune diseases.

    Tip Ranks·
    US
    JBIO
    -1.50%
    Tip Ranks·
    US
    JBIO
    -1.50%

    Jade Biosciences | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    JBIO
    -1.50%
    LB filings·
    US
    JBIO
    -1.50%

    Jade Biosciences | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    JBIO
    -1.50%
    LB filings·
    US
    JBIO
    -1.50%